Abstract
Forty percent of hypertensive type 2 diabetes patients develop nephropathy (microalbuminuria/overt nephropathy), indicating end organ damage, increased risk of cardiovascular disease (CVD), and death. In France, screening rates and nephropathy treatment are suboptimal. We assessed the health economic impact of nephropathy screening in hypertensive patients with type 2 diabetes followed by optimal antihypertensive/nephroprotective therapy in those who have nephropathy in France. A Markov/Monte Carlo model simulated lifetime impacts of screening for albuminuria (microalbuminuria/overt nephropathy) using semi-quantitative urine dipsticks in a primary care setting, and subsequent addition of irbesartan 300 mg to conventional therapy in hypertensive type 2 diabetes patients identified as having nephropathy. Progression from no renal disease to end-stage renal disease (ESRD) was simulated. Probabilities, utilities and costs of CVD events, medications and ESRD treatment came from published sources. Cumulative incidence of ESRD, life expectancy, quality-adjusted life years (QALYs) and direct costs were projected. Second-order Monte Carlo simulation accounted for uncertainty in multiple parameters. Costs and QALYs were discounted at 3% ...Continue Reading
References
Nov 1, 1989·Contraception
Dec 16, 1995·BMJ : British Medical Journal·B A Kiberd, K K Jindal
Jan 15, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·B A Kiberd, K K Jindal
Nov 16, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·E RitzS Halimi
Aug 5, 2000·Journal of Diabetes and Its Complications·G C BrownP Denton
Sep 8, 2000·PharmacoEconomics·A H Briggs
Nov 30, 2000·Journal of Human Hypertension·J P VoraG L Bakris
Feb 13, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C CombeUNKNOWN French Study Group Nutrition in Dialysis
Feb 15, 2001·Advances in Renal Replacement Therapy·B CharraC Chazot
Apr 6, 2001·Diabetes Care·S H SaydahF L Brancati
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Jul 24, 2002·Diabetologia·B Jönsson, UNKNOWN CODE-2 Advisory Board
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jul 28, 2004·Diabetes Care·Andrew J PalmerHans-Henrik Parving
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Jun 17, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Eberhard Ritz
Citations
Jul 17, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Maarten J Postma, Dick de Zeeuw
Nov 1, 2007·International Journal of Clinical Practice·M Volpe
Mar 19, 2008·Clinical Drug Investigation·Antonio Coca
Jun 16, 2011·PharmacoEconomics·Joseph MenzinTracy Mayne
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Brooke S HarrowZhao Chen
Feb 18, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Paul KomendaNavdeep Tangri
Dec 29, 2016·Diabetes/metabolism Research and Reviews·D R WebbK Khunti
Oct 2, 2019·PharmacoEconomics·Daniel M SugrueHeleen G M van Haalen
Jul 17, 2008·Drugs·Katherine F Croom, Greg L Plosker
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity